Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis.
Using a rat model of intraperitoneal abscess due to Bacteroides fragilis, we evaluated therapy with the combination of ceftriaxone plus the beta-lactamase inhibitor tazobactam in comparison with ceftriaxone or cefotaxime alone. When treatment was begun five hours after bacterial challenge, final bacterial counts within abscesses at 3.5 days of treatment were as follows (mean +/- S.D., log10 cfu/g): ceftriaxone plus tazobactam, 4.15 +/- 1.25; cefotaxime, 4.77 +/- 1.80; ceftriaxone alone, 5.68 +/- 1.04; untreated controls, 9.14 +/- 1.13. In spite of pharmacokinetic differences between the two drugs, coadministration of tazobactam significantly enhanced activity of ceftriaxone in this model.
Pefanis
A
A
Department of Medicine, New England Deaconess Hospital, Boston, MA 02215.
Thauvin-Eliopoulos
C
C
Eliopoulos
G M
GM
Moellering
R C
RC
D000005:Abdomen; D000038:Abscess / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D001442:Bacteroides Infections / Q000097:blood / Q000188:drug therapy*; D001441:Bacteroides fragilis; D002443:Ceftriaxone / Q000097:blood / Q000494:pharmacology*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D008297:Male; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D010532:Peritoneal Diseases / Q000097:blood / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000078142:Tazobactam
D002443:Ceftriaxone; D010397:Penicillanic Acid; D000078142:Tazobactam